DLDongmei Li

Dongmei Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dongmei Li has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Wenxing He

    Breast Cancer Center, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, China

    2 shared publications
  • Haoyi Zhang

    School of Public Health, Nanchang University, Nanchang, China

    1 shared publication
  • Hong Cheng

    Breast Cancer Center, Jiangxi Cancer Hospital of Nanchang Medical College, Nanchang, People’s Republic of China

    1 shared publication
  • Jianfeng Wen

    Hospital 908 of the Joint Support Force of the Chinese People’s Liberation Army, Nanchang, China

    1 shared publication
  • Tenghua Yu

    Breast Cancer Center, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, China

    1 shared publication
  • Wenxing He

    Breast Cancer Center,Jiangxi Cancer Hospital of Nanchang University;Jiangxi Key Laboratory of Translational Research for Cancer,No. 519 East Beijing Road, Nanchang, Jiangxi, 330029, China

    1 shared publication

Latest Publications

  • Open Access

    Significance of SUMOylation in breast cancer progression: a comprehensive investigation using single-cell analysis and bioinformatics

    by Wenxing He, Zhengkui Sun, Dongmei Li, Tenghua Yu

    Background: Breast cancer remains a major global health challenge because of limitations in early detection and therapeutic outcomes. This study employed bulk and single-cell RNA sequencing to investigate SUMOylation-associated molecular networks, aiming to identify prognostic biomarkers and potential therapeutic applications. Methods: Transcriptomic profiling was performed on 1,445 breast cancer and 113 normal samples to identify differentially expressed genes. Four hub genes, NR3C2 , CDCA8 , AURKA , and PLK1 , were prioritized using machine learning. Consensus clustering stratified patients into molecular subtypes based on the hub gene expression patterns. Differential immune infiltration analysis was used to evaluate 28 immune cell populations between the subtypes. Hub gene-immune cell interactions were visualized using bubble diagrams. Pharmacogenomic sensitivity profiling was performed using subtype-specific drug response data. Single-cell sequencing identified epithelial subclusters enriched for hub genes, and transcription factor networks were analyzed using SCENIC. Pan-cancer validation was performed to assess the oncogenic role of hub genes in 21 malignancies. Statistical significance was determined using the Student’s t -test ( p < 0.0001). Results: Tumor tissues exhibited significant upregulation of CDCA8 , AURKA , and PLK1 , whereas NR3C2 was notably downregulated ( p < 0.0001). Consensus clustering identified two distinct molecular subtypes: Subtype1, characterized by NR3C2 upregulation and poorer prognosis, and Subtype2, distinguished by enhanced expression of CDCA8 , AURKA , and PLK1 , correlating with favorable outcomes. Notably, PIK3CA mutations were prevalent in Subtype1, whereas TP53 mutations dominated Subtype2. Immune infiltration profiles differed significantly between the two subtypes for most immune cell types. Pharmacogenomic assessments revealed distinct drug sensitivity profiles for each subtype in response to various therapeutic agents. A pan-cancer analysis of the four hub genes demonstrated consistent expression patterns, immune correlations, and prognostic associations across malignancies. Conclusion: Our findings reveal that SUMOylation subtypes in breast cancer exhibit distinct prognostic, immunological and pharmacogenomic profiles. These insights may provide candidate biomarkers for future personalized treatment strategies for breast cancer and potentially for other malignancies.


  • Open Access

    PIK3CD correlates with prognosis, epithelial–mesenchymal transition and tumor immune infiltration in breast carcinoma

    by Wenxing He, Haoyi Zhang, Hong Cheng, Jianfeng Wen, Dongmei Li

    Background: Breast carcinoma (BRCA) is one of the most common, fatal, and aggressive cancers, with increasing morbidity that has a major impact on human health. PIK3CD appears to have important roles in the beginning and advancement of various forms of human cancer, according to mounting data. However,the particular role and mechanism of PIK3CD in BRCA remains not fully identified. Methodology: The Cancer Genome Atlas (TCGA, https://portal.gdc.cancer.gov/), Genotype-Tissue Expression (GTEx) data and the UCSC Xena browser (https://xenabrowser.net) data were used in this study’s initial pan-cancer analysis of PIK3CD expression and prognosis. Circular RNAs (circRNAs) that regulated the expression of PIK3CD were subsequently found using a combination of in silico investigations of expression, correlation, and survival. Measurements of PIK3CD expression and an analysis of the in vitro function of PIK3CD in BRCA cells were performed using real-time RT-PCR, Western blotting and Transwell assays. Results: In BRCA GLI2, RAB32, LAMB1, MGAT2, ITGA8, CHF, COL6A3 and PRRX1-miR-30b-5p axis was identified as the most likely upstream CircRNA-related route of PIK3CD. PIK3CD was correlated with the expression of EMT markers. The PIK3CD cDNA improved the capacity for invasion and migration. The expression of PIK3CD was linked to some of the m1A/m5C/m6A regulators. Additionally, it was discovered that the expression of PIK3CD was found to be highly connected to the expression of immunological checkpoints, immune cell biomarkers, and tumor immune cell invasion. Conclusions: Our findings reveal that PIK3CD expression is associated with prognosis, EMT, and tumor immune infiltration in BRCA patients.